DMTT.F Stock Overview
Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Small Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.11 |
| 52 Week High | CA$0.16 |
| 52 Week Low | CA$0.045 |
| Beta | 0.86 |
| 1 Month Change | -19.76% |
| 3 Month Change | 108.40% |
| 1 Year Change | -12.32% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -69.01% |
Recent News & Updates
Recent updates
Shareholder Returns
| DMTT.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -9.7% | 1.4% | 1.7% |
| 1Y | -12.3% | 14.9% | 26.0% |
Return vs Industry: DMTT.F underperformed the US Pharmaceuticals industry which returned -4.4% over the past year.
Return vs Market: DMTT.F underperformed the US Market which returned 15.2% over the past year.
Price Volatility
| DMTT.F volatility | |
|---|---|
| DMTT.F Average Weekly Movement | 22.0% |
| Pharmaceuticals Industry Average Movement | 9.8% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DMTT.F's share price has been volatile over the past 3 months.
Volatility Over Time: DMTT.F's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | n/a | George Tziras | www.smallpharma.com |
Small Pharma Inc., a biotechnology company, focuses on developing short-duration psychedelic-assisted therapies for the treatment of mental health conditions. Its clinical program is based on N,N, dimethyltryptamine, a naturally occurring psychoactive molecule. The company’s product includes SPL026, which is in clinical Phase IIa for the treatment of major depressive disorder; and SPL028, an injectable formulation of deuterated DMT, which is in Phase 1 clinical trial, as well as SPL801B, an oral dosage.
Small Pharma Inc. Fundamentals Summary
| DMTT.F fundamental statistics | |
|---|---|
| Market cap | US$36.45m |
| Earnings (TTM) | -US$13.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs DMTT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DMTT.F income statement (TTM) | |
|---|---|
| Revenue | CA$0 |
| Cost of Revenue | CA$0 |
| Gross Profit | CA$0 |
| Other Expenses | CA$19.31m |
| Earnings | -CA$19.31m |
Last Reported Earnings
Aug 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.058 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did DMTT.F perform over the long term?
See historical performance and comparison